Drug Screening Market Trends, Share, Growth Rate - Healthcare Industry Research Reports

Breaking

About Me

Healthcare Research Reports

Friday, July 13, 2018

Drug Screening Market Trends, Share, Growth Rate


The drug screening market is expected to reach USD 8.63 billion by 2022 from USD 5.32 billion in 2017, at a CAGR of 10.2%. Factors such as growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, and the availability of government funding in major markets are driving the growth of this market.



Most key players adopted product launches as the primary growth strategy between 2014 and 2017. Some of the companies that adopted this strategy include Alfa Scientific Designs, Thermo Fisher, and Premier Biotech.

The drug screening market is highly competitive with the presence of several big and small players. Prominent players offering products for drug screening include Alere (US), Thermo Fisher (US), Drägerwerk (Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc. (US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (Germany). While, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada), and CannAmm (Canada) are the leading players in the market.

Alere is a leader in the rapid testing devices market because of the broad product portfolio if offers. Alere provides oral fluid screening devices, urine drug testing devices, and breath alcohol testing devices. The company also provides urine, oral, and hair drug screening services for offices, drug treatment centers, pain management centers, and hospitals. Serving such a wide range of customers will help the company gain a competitive edge over other players in the market. 

Alere focuses on adopting both organic and inorganic growth strategies such as partnerships and collaborations to maintain its leading position in the market. For instance, in 2017, Alere (US) entered into partnership with MinuteClinic (US). As per this agreement, MinuteClinic joined the Alere eScreen Occupational Health Network (EOHN) and employees of those businesses that utilize Alere eScreen’s services in more than 1,100 MinuteClinic locations in the US for required workplace drug testing. Moreover, Alere has a strong geographic presence across North America, Europe, the Middle East, Asia Pacific, Latin America, and Africa. This strong network also enables Alere to distribute products across the globe efficiently.

LabCorp is the leading player in the US drug screening services market. The company has a strong brand value and a robust service portfolio. LabCorp provides drug screening services to managed care organizations, governmental agencies, physicians, and other healthcare providers, hospital and health systems, employers, patient and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has a strong network of 39 laboratories and 1,700 patient service centers, and a network of branches and STAT laboratories across the US, Canada, and the UK. 

Over the past three years, the company adopted acquisitions as its key growth strategy. For instance, in 2017, LabCorp (US) acquires Bode Technology (UK). This enabled the company to expand its service offerings in the drug screening services market.

To Know More @






No comments:

Post a Comment